CARMEL, Ind., Jan. 30, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today another contract win from the Maricopa County Department of Public Health to provide public health training.
Under the new agreement, Syra Health will deliver its Foundations of Public Health training to employees of the Maricopa County Department of Public Health as well as community-based organizations. The goal of the training is to advance public health awareness.
The customized training provided by Syra Health's public health experts will include information about the historical evolution of public health, the importance of public health and health equity, public health influences, and how to impact public health positively. The training will also include the role of public health departments and how to collaborate with those departments.
This is the second contract awarded to Syra Health by Maricopa County for healthcare training. In October of 2023, Syra Health announced it had successfully trained over 100 public health staff in Maricopa County, based on the training evaluations received. Like the health equity training, Syra Health will provide pre-and post-assessments to trainees to assess the value of the Foundations of Public Health training.
"We are continuing to win these types of contracts because of our public health expertise, said Dr. Deepika Vuppalanchi, CEO, Syra Health." We provide a meaningful impact to relevant stakeholders who otherwise wouldn't have ready access to public health information specific to their particular region.
Just last week Syra Health announced a contract extension in Maricopa County, where the Company also provides its healthcare workforce solutions in support of Maricopa County's Correctional Health Services.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors outlined in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications & Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.94 |
Daily Change: | -0.06 -5.86 |
Daily Volume: | 138,116 |
Market Cap: | US$6.220M |
August 08, 2024 July 30, 2024 May 14, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB